Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (January 2022)
29 slides from Sonoma Pharmaceuticals's investor presentation, Jan 6, 2022
Slide 1: Sonoma Pharmaceuticals, Inc. January 2022
Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA January 2022
Slide 2: Legal Disclaimers
Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness
Slide 3: Legal Disclaimers: Non-GAAP, Trademarks
Legal Disclaimers NON - GAAP FINANCIAL MEASURES Non - GAAP income (loss) from operations minus non - cash expenses (EBITDAS) is a non - GAAP financial measure. The Company defines operating income (loss) minus non - cash expenses as GAAP reported operating income (loss) minus operating depreciation
Slide 4: About Sonoma
About Sonoma Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid ( HOCl ) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company’s produ
Slide 5: Investor Highlights
Investor Highlights Diverse global healthcare leader • Focused on billion - dollar Rx and OTC wound care, dermatology, eye, oral and nasal care, disinfectant use and animal health markets • Over 20 years of experience • Robust international partner network • Focused on expanding U.S. partner network
Slide 6: Key Opportunities
Key Opportunities • Expand OTC reach in U.S. in the dermatology, eye, oral and nasal care, disinfectants and wound care markets • Fully commercialize existing products via distribution partners or directly • 21 U.S. FDA clearances as medical devices for Section 510(k) • CEs for over 39 products • Ex
Slide 7: Recent Business Developments
Recent Business Developments • Partnered with EMC Pharma, LLC for exclusive distribution into prescription - based dermatology, eye, oral and nasal care products in the U.S. in March 2021. • Launched completely revamped website at www.sonomapharma.com in July 2021. The new website highlights the glo
Slide 8: Sonoma's Microcyn Technology
Sonoma’s Microcyn Technology • Stable triple - action topical technology • A powerful anti - microbial - reduces microbial load, including destruction of biofilms • Anti - inflammatory agent – reduces itch and pain • Anti - pruritic activity • Tissue healing (increased blood/oxygen flow to wound) •
Slide 9: What is Hypochlorous Acid?
What is Hypochlorous Acid? During the activation of neutrophils, respiratory bursts generate hydrogen peroxide (H 2 O 2 ) and the activated granule enzyme myeloperoxidase converts H 2 O 2 to hypochlorous acid (HOCl) • Hypochlorous acid (HOCl) is produced by neutrophils in the body as part of its def
Slide 10: Microcyn Technology microbial load reduction & infection control
Microcyn Technology microbial load reduction & infection control 30 seconds “ in vitro kill time (%) reduction” • MRSA - Staphylococcus aureus 99.999 VRE - Enterococcus faecalis 99.999 • Staphylococcus aureus 99.999 Escherichia coli 99.997 • Acinetobacter baumannii 99.999 Bacteroides fragilis 99.999
Slide 11: Current Research and Development
Current Research and Development • Dermodacyn ® Disinfecting solution study on viability of SARS - CoV - 2, see https://www.sciencedirect.com/science/article/pii/S019567012030339X • Endocyn ® study on cellular toxicity, see https://www.sciencedirect.com/science/article/abs/pii/S0099239917310439 • HO
Slide 12: U.S. Summary
U.S. Summary • FDA - cleared products targeting: • atopic dermatitis, dermal lesions • scar management, • pain and itch relief and other dermatological conditions • eyelid and eyelash hygiene • acute and chronic wound care • oral care (dental surgery) • Ability to partner for OTC, Rx, and private la
Slide 13: Attractive U.S. Product Offerings
Attractive U.S. Product Offerings
Slide 14: Cont. U.S Product Offerings
14 NASDAQ: SNOA Cont. U.S Product Offerings
Slide 15: Robust International Distribution Network
Robust International Distribution Network • Steadily growing existing partner base with broad indications • ISO/FDA registered/CE/EN/MOH/TGA registrations for state - of - the - art Mexico manufacturing facility • Ship to 54 countries globally • 40+ partners in dermatology, eye, wound, oral and nasa
Slide 16: State of the Art Manufacturing Facility
State of the Art Manufacturing Facility • ISO 9001 and 13485 certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and many other national listing/approvals • Shipping to 54 countries • First Rate Logistics • Highest Quality Standards • Flexibility of SKUs and packaging • Highly - trained staff
Slide 17: Europe
Europe
Slide 18: Latin America
Latin America
Slide 19: Asia
Asia
Slide 20: Middle East
Middle East
Slide 21: Animal Health Care
21 NASDAQ: SNOA Animal Health Care • MicrocynAH ® is a family of advanced animal healthcare products that are safe to use on all animals, no matter the species or age • Perfect for hot spots, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • We
Slide 22: Sonoma Partnership Principles
Sonoma Partnership Principles • Sonoma seeks long - term strategic partnerships, based on win/win business plans; 50/50 mentality with focus on what’s most important to each side. • Regular in - person and phone meetings to strengthen relationships. • “Do what you say and say what you do” mentality
Slide 23: Key Financial Metrics
Key Financial Metrics Quarter Ended Quarter Ended Six Months Ended S ix Months Ended Sept 30 , 2021* (unaudited) Sept 30, 2020* (unaudited) Sept 30, 2021* (unaudited) Sept 30, 2020* (unaudited) Total Revenues $3,744 $5,769 $7,428 $11,536 Gross Profit $1,241 $2,502 $2,694 $4,757 Operating Expenses $2
Slide 24: Balance Sheet Highlights
Balance Sheet Highlights (in thousands) September 30, 2021 (unaudited) March 31, 2021 Assets Cash and cash equivalents 8,392$ 4,220$ Accounts receivable, net 3,416 2,806 Inventories 2,482 2,530 Other current assets 3,731 3,427 Total Current Assets 18,021 12,983 Other assets 1,807 2,004 TOTAL ASSETS
Slide 25: Income Statement, Sept. 30, 2021
Income Statement, Sept. 30, 2021 (unaudited, in thousands, except per share amounts) 2021 2020 2021 2020 Revenues 3,744$ 5,769$ 7,428$ 11,536$ Cost of revenue 2,503 3,267 4,734 6,779 Gross profit 1,241 2,502 2,694 4,757 Operating expenses Research and development 10 (85) 95 391 Selling, general and
Slide 26: Statement of Cash Flows
Statement of Cash Flows, June 30, 2021 (unaudited, in thousands) 2021 2020 Net cash used in operating activities (2,527)$ (2,648)$ Net cash (used in) provided by investing activities (38) 475 Net cash provided by financing activities 6,711 2,797 Effect of exchange rates on cash and cash equivalents
Slide 27: Revenue Metrics (Three Months)
Revenue Metrics (unaudited, in thousands) 2021 2020 Change % Change Revenue by revenue sources: Human 2,591$ 4,776$ (2,185)$ -45.75% Animal 1,005 951 54 5.68% Service and Royalty 148 42 106 252.38% 3,744$ 5,769$ (2,025)$ -35.10% Revenue by geographic area: United States 1,347$ 1,984$ (637)$ -32.11%
Slide 28: Revenue Metrics (Six Months)
Revenue Metrics (unaudited, in thousands) 2021 2020 Change % Change Revenue by revenue sources: Human 5,186$ 10,094$ (4,908)$ -48.62% Animal 1,937 1,388 549 39.55% Service and Royalty 305 54 251 464.81% 7,428$ 11,536$ (4,108)$ -35.61% Revenue by geographic area: United States 2,939$ 3,605$ (666)$ -1
Slide 29: Thank You.
Thank You.
Sonoma Pharmaceuticals — Investor Presentation (January 2022) on 6ix